News & Updates

Antibiotics are usually prescribed by physicians to patients hospitalized with decompensated cirrhosis even without an infection diagnosis, according to a UK study. However, this practice has neither reduced the overall risk of hospital-acquired infections (HAI) nor improved survival.

Use of a novel drug delivery system (DDS) to deliver a therapeutic compound in the colon has been successful, achieving the intended function with no serious adverse events, reports a study presented at the recent Crohn’s & Colitis Congress (CCC 2023).

Adherence to gluten-free diet (GFD) in individuals with celiac disease and inflammatory bowel disease (IBD) appears to be low, according to a study.

Ulcerative colitis (UC) flare at 12 months has occurred in more than half of UC patients with tofacitinib dose de-escalation, according to a study presented at the recent Crohn’s & Colitis Congress (CCC 2023). Factors associated with UC flare following de-escalation are shorter induction course (<16 weeks) and active disease at 6 months of tofacitinib.

Among adults with type 2 diabetes, the risk of developing chronic kidney disease is high in the presence of metabolic dysfunction-associated fatty liver disease (MAFLD), as shown in a study.

Patients with ulcerative colitis (UC) who achieve early partial Mayo score (PMS) remission with vedolizumab are more likely to attain week 52 remission than delayed responders, suggests a study.